A Phase I, Randomized, Double-blind, Placebo-controlled Study of Intravenous SHR0410 to Evaluate Safety and Pharmacokinetics in Hemodialysis Participants.
Latest Information Update: 04 Nov 2021
At a glance
- Drugs SHR-0410 (Primary)
- Indications Pruritus
- Focus Adverse reactions
- Sponsors Atridia
Most Recent Events
- 08 Jul 2020 Status changed from recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 02 Jul 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2019.